The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
Aaron WinklerWeiyong SunSaurav DeAiping JiaoM Nusrat SharifPeter T SymanowiczShruti AthaleJulia H ShinJu WangBruce A JacobsonSimeon J RamseyKen DowerTatyana AndreyevaHeng LiuMartin HegenBruce L HomerJoanne BrodfuehrerMera TilleySteven A GilbertSpencer I DantoJean J BeebeBetsy J BarnesVirginia PascualLih-Ling LinIain KiltyMargaret FlemingVikram R RaoPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
These data demonstrate that inhibition of IRAK4 kinase activity can reduce levels of inflammation markers in humans and provide confidence in the rationale for clinical development of IRAK4 inhibitors for rheumatologic indications.